Merck CEO Richard Clark (photo [1]) has been using the company's annual business briefing to tout its reorganization efforts. More than half of the 7,000 announced job cuts [2] have been made and Merck launched [3] five new vaccines [4] this year. Clark added that Merck has eight more products on the horizon, including three receiving regulatory scrutiny. NDAs for HIV, insomnia and heart disease are planned for 2007. Merck also faces 27,200 lawsuits over Vioxx. Report [5]
Links:
[1] http://www.fiercebiotech.com/node/4562
[2] http://www.fiercebiotech.com/story/struggling-merck-plans-7-000-pink-slips-plant-closings/2005-11-28
[3] http://www.fiercebiotech.com/story/merck-s-gardasil-ok-d-for-pricey-rollout/2006-06-09
[4] http://www.fiercebiotech.com/story/merck-wins-fda-emea-approval-for-zostavax/2006-05-26
[5] http://www.iht.com/articles/ap/2006/12/12/business/NA_FIN_COM_US_Merck_Outlook.php